VistaGen Therapeutics (VTGN) Competitors $2.55 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$2.52 -0.02 (-0.98%) As of 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTGN vs. ZYBT, CRDF, MREO, KOD, MNPR, TSVT, AARD, PRQR, INZY, and TRDAShould you be buying VistaGen Therapeutics stock or one of its competitors? The main competitors of VistaGen Therapeutics include Zhengye Biotechnology (ZYBT), Cardiff Oncology (CRDF), Mereo BioPharma Group (MREO), Kodiak Sciences (KOD), Monopar Therapeutics (MNPR), 2seventy bio (TSVT), Aardvark Therapeutics (AARD), ProQR Therapeutics (PRQR), Inozyme Pharma (INZY), and Entrada Therapeutics (TRDA). These companies are all part of the "pharmaceutical products" industry. VistaGen Therapeutics vs. Its Competitors Zhengye Biotechnology Cardiff Oncology Mereo BioPharma Group Kodiak Sciences Monopar Therapeutics 2seventy bio Aardvark Therapeutics ProQR Therapeutics Inozyme Pharma Entrada Therapeutics Zhengye Biotechnology (NASDAQ:ZYBT) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability. Does the media prefer ZYBT or VTGN? In the previous week, VistaGen Therapeutics had 2 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 3 mentions for VistaGen Therapeutics and 1 mentions for Zhengye Biotechnology. VistaGen Therapeutics' average media sentiment score of 1.02 beat Zhengye Biotechnology's score of 0.00 indicating that VistaGen Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zhengye Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral VistaGen Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ZYBT or VTGN more profitable? Zhengye Biotechnology has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -6,777.08%. Zhengye Biotechnology's return on equity of 0.00% beat VistaGen Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Zhengye BiotechnologyN/A N/A N/A VistaGen Therapeutics -6,777.08%-58.88%-52.38% Which has better earnings and valuation, ZYBT or VTGN? Zhengye Biotechnology has higher revenue and earnings than VistaGen Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZhengye Biotechnology$186.36M1.44$1.55MN/AN/AVistaGen Therapeutics$490K151.75-$51.42M-$1.66-1.54 Do institutionals and insiders believe in ZYBT or VTGN? 78.4% of VistaGen Therapeutics shares are held by institutional investors. 1.3% of VistaGen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts rate ZYBT or VTGN? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00VistaGen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryVistaGen Therapeutics beats Zhengye Biotechnology on 7 of the 12 factors compared between the two stocks. Get VistaGen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VTGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTGN vs. The Competition Export to ExcelMetricVistaGen TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$74.36M$2.91B$5.48B$9.44BDividend YieldN/A2.48%4.00%4.04%P/E Ratio-1.5419.8028.1119.80Price / Sales151.75231.40421.3989.14Price / CashN/A40.8024.9928.17Price / Book1.057.648.145.70Net Income-$51.42M-$55.16M$3.24B$257.84M7 Day Performance7.14%1.84%1.13%1.88%1 Month Performance27.50%13.83%8.40%13.28%1 Year Performance-30.33%4.19%34.01%19.16% VistaGen Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTGNVistaGen Therapeutics0.7182 of 5 stars$2.55flatN/A-30.3%$74.36M$490K-1.5440Positive NewsHigh Trading VolumeZYBTZhengye BiotechnologyN/A$5.87-0.3%N/AN/A$276.86M$186.36M0.00278Positive NewsCRDFCardiff Oncology0.9054 of 5 stars$4.13+1.5%$11.70+183.3%+90.2%$274.77M$680K-4.4920MREOMereo BioPharma Group1.8376 of 5 stars$1.72+6.8%$7.20+318.6%-54.4%$273.48M$10M-24.5740Analyst DowngradeHigh Trading VolumeKODKodiak Sciences3.7285 of 5 stars$5.17+14.1%$9.00+74.1%+92.3%$272.77MN/A-1.4290MNPRMonopar Therapeutics2.4339 of 5 stars$43.73+18.6%$60.00+37.2%+1,277.2%$267.63MN/A-12.5710TSVT2seventy bioN/A$5.00flat$5.00N/A$266.15M$48.37M-2.69440AARDAardvark TherapeuticsN/A$12.11-0.5%$33.00+172.5%N/A$262.74MN/A0.0018PRQRProQR Therapeutics2.1382 of 5 stars$2.48+6.9%$8.00+222.6%+26.6%$260.92M$20.46M-7.09180INZYInozyme Pharma2.8787 of 5 stars$4.00flat$11.75+193.8%N/A$258.25MN/A-2.3750TRDAEntrada Therapeutics2.8926 of 5 stars$6.80+3.8%$25.67+277.5%-63.1%$258.08M$172.22M8.40110 Related Companies and Tools Related Companies ZYBT Alternatives CRDF Alternatives MREO Alternatives KOD Alternatives MNPR Alternatives TSVT Alternatives AARD Alternatives PRQR Alternatives INZY Alternatives TRDA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTGN) was last updated on 7/21/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VistaGen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VistaGen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VTGN Stock Alerts